Highlights Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/12/2025 GMT			5-day change	1st Jan Change
11.92 ^USD	-3.95%		-33.13%	-47.66%

12-05	Top Premarket Decliners	MT
11-11	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	CI

Highlights

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	11-11	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	11-06	CI
Quoin Pharmaceuticals Ltd. Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 Month 'Whole Body' Data Update from Ongoing Study	10-28	CI
Quoin Pharmaceuticals announces U.S. FDA grants orphan drug designation for QRX003 in Netherton Syndrome	10-21	RE
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	08-07	CI
Quoin Pharmaceuticals Ltd. Releases New Netherton Now Video Featuring Professor Mellerio, International Expert in Genetic Skin Diseases	06-26	CI
Quoin Pharmaceuticals Ltd. Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome	06-24	CI
Certain Warrants of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	06-24	CI
Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate Second Pivotal Whole Body Qrx003 Netherton Syndrome Clinical Study	05-22	CI
Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study	05-22	MT
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study	05-14	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-13	CI
Quoin Pharmaceuticals Regains Compliance With Nasdaq	04-30	RE
Quoin Pharmaceuticals Ltd. Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of A Second Pediatric Patient	04-02	CI
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases	03-25	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	03-13	CI
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications	03-04	CI
Quoin Pharmaceuticals Ltd. Announces Highly Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study	02-27	CI
Quoin Pharmaceuticals Ltd. Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome	01-23	CI
Quoin Pharmaceuticals Ltd. Announces Positive Clinical Data from its Ongoing Pediatric Netherton Syndrome Study	01-16	CI
Quoin Pharmaceuticals Ltd. Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study	01-06	CI
Quoin Pharmaceuticals Prices $6.8 Million Equity Offering -- Shares Fall	12-20	MT
Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study	12-19	CI
Quoin Pharmaceuticals, Ltd. Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies	12-18	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Highlights

Filters